Advertisement
ABBV vs CURE
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABBV is a Buy and CURE is a StrongBuy.
ABBV's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for ABBV turned positive on October 07, 2026. Looking at past instances where ABBV's MACD turned positive, the stock continued to rise in 34 of 46 cases over the following month. The odds of a continued upward trend are 74%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 05, 2026. You may want to consider a long position or call options on ABBV as a result. In 55 of 77 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 71%.
Following a +1.30% 3-day Advance, the price is estimated to grow further. Considering data from situations where ABBV advanced for three days, in 220 of 361 cases, the price rose further within the following month. The odds of a continued upward trend are 61%.
The Aroon Indicator entered an Uptrend today. In 228 of 357 cases where ABBV Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 64%.
Bearish Trend Analysis
The 10-day RSI Indicator for ABBV moved out of overbought territory on October 21, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 46 similar instances where the indicator moved out of overbought territory. In 14 of the 46 cases, the stock moved lower in the following days. This puts the odds of a move lower at 30%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 10 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABBV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 46%.
ABBV broke above its upper Bollinger Band on October 07, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 1 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 2 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 61, placing this stock better than average.
The Tickeron Valuation Rating of 3 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: ABBV's P/B Ratio (-84.798) is very low in comparison to the industry average of (-3.196). ABBV has a moderately high P/E Ratio (80.452) as compared to the industry average of (21.213). Projected Growth (PEG Ratio) (0.544) is also within normal values, averaging (5.738). Dividend Yield (0.024) settles around the average of (0.041) among similar stocks. ABBV's P/S Ratio (7.231) is slightly higher than the industry average of (4.033).
The Tickeron Price Growth Rating for this company is 10 (best 1 - 100 worst), indicating outstanding price growth. ABBV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 73 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
CURE's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for CURE turned positive on October 09, 2026. Looking at past instances where CURE's MACD turned positive, the stock continued to rise in 42 of 46 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on CURE as a result. In 85 of 95 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 89%.
CURE moved above its 50-day moving average on October 14, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for CURE crossed bullishly above the 50-day moving average on October 15, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Following a +13.38% 3-day Advance, the price is estimated to grow further. Considering data from situations where CURE advanced for three days, in 290 of 323 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.
The Aroon Indicator entered an Uptrend today. In 228 of 247 cases where CURE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.
Bearish Trend Analysis
The 10-day RSI Indicator for CURE moved out of overbought territory on October 21, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 similar instances where the indicator moved out of overbought territory. In 29 of the 31 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CURE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
CURE broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
ABBV | ||
|---|---|---|
OUTLOOK RATING 1..100 | 43 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 3 Undervalued | |
PROFIT vs RISK RATING 1..100 | 2 | |
SMR RATING 1..100 | 1 | |
PRICE GROWTH RATING 1..100 | 10 | |
P/E GROWTH RATING 1..100 | 73 | |
SEASONALITY SCORE 1..100 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| ABBV | CURE | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 30% | 2 days ago 90% |
| Stochastic ODDS (%) | 2 days ago 41% | 2 days ago 90% |
| Momentum ODDS (%) | 2 days ago 71% | 2 days ago 89% |
| MACD ODDS (%) | 2 days ago 74% | 2 days ago 90% |
| TrendWeek ODDS (%) | 2 days ago 63% | 2 days ago 90% |
| TrendMonth ODDS (%) | 2 days ago 64% | 2 days ago 90% |
| Advances ODDS (%) | 7 days ago 61% | 8 days ago 90% |
| Declines ODDS (%) | 22 days ago 46% | 4 days ago 90% |
| BollingerBands ODDS (%) | 2 days ago 38% | 2 days ago 90% |
| Aroon ODDS (%) | 2 days ago 64% | 2 days ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ABBV’s FA Score shows that 4 FA rating(s) are green while .
- ABBV’s FA Score: 4 green, 1 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ABBV’s TA Score shows that 4 TA indicator(s) are bullish.
- ABBV’s TA Score: 4 bullish, 4 bearish.
Price Growth
ABBV (@Pharmaceuticals: Major) experienced а +1.08% price change this weekfor the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +0.73%. For the same industry, the average monthly price growth was -4.97%, and the average quarterly price growth was +5.45%.
Reported Earning Dates
ABBV is expected to report earnings on Oct 30, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (+0.73% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
Advertisement
ABBV and
Correlation & Price change
A.I.dvisor indicates that over the last year, ABBV has been loosely correlated with NVS. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if ABBV jumps, then NVS could also see price increases.
| Ticker / NAME | Correlation To ABBV | 1D Price Change % | ||
|---|---|---|---|---|
| ABBV | 100% | -1.48% | ||
| NVS - ABBV | 50% Loosely correlated | +0.19% | ||
| JNJ - ABBV | 49% Loosely correlated | -0.61% | ||
| AMGN - ABBV | 48% Loosely correlated | -0.14% | ||
| BMY - ABBV | 47% Loosely correlated | -0.91% | ||
| BIIB - ABBV | 41% Loosely correlated | -0.87% | ||
More | ||||
CURE and
Correlation & Price change
A.I.dvisor indicates that over the last year, CURE has been closely correlated with LLY. These tickers have moved in lockstep 73% of the time. This A.I.-generated data suggests there is a high statistical probability that if CURE jumps, then LLY could also see price increases.
| Ticker / NAME | Correlation To CURE | 1D Price Change % | ||
|---|---|---|---|---|
| CURE | 100% | -1.28% | ||
| LLY - CURE | 73% Closely correlated | -1.01% | ||
| MRK - CURE | 66% Closely correlated | +1.07% | ||
| ABBV - CURE | 63% Loosely correlated | -1.48% | ||
| JNJ - CURE | 63% Loosely correlated | -0.61% | ||
| BMY - CURE | 59% Loosely correlated | -0.91% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| FXL | 222.02 | 4.25 | +1.95% |
| First Trust Technology AlphaDEX Fund (FXL) | |||
| ESG | 183.05 | 0.92 | +0.51% |
| Northern Trust STOXX US ESG Select ETF (ESG) | |||
| VGVT | 72.58 | 0.01 | +0.02% |
| Vanguard Government Securities Active ETF (VGVT) | |||
| TINS | 28.04 | N/A | N/A |
| Templeton International Insights ETF (TINS) | |||
| WIP | 38.46 | -0.05 | -0.13% |
| State Street SPDR FTSE International Government Inflation-Protected Bond ETF (WIP) | |||